Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.

Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.

Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.

Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2?,4?-bridged nucleic acids, 2?,4?-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2?,4?-non-bridged nucleic acid residue(s) is/are modified.

Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2?,4?-bridged nucleic acids, 2?,4?-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2?,4?-non-bridged nucleic acid residue(s) is/are modified.

Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2?,4?-bridged nucleic acids, 2?,4?-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2?,4?-non-bridged nucleic acid residue(s) is/are modified.

Abstract: A compound represented by formula I or II below or a salt thereof: wherein B1 represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group that has any one or more substituents selected from the group consisting of a hydroxyl group, a hydroxyl group protected by a protecting group in nucleic acid synthesis, a C1 to C6 linear alkyl group, a C1 to C6 linear alkoxy group, a mercapto group, a mercapto group protected by a protecting group in nucleic acid synthesis, a C1 to C6 linear alkylthio group, an amino group, a C1 to C6 linear alkylamino group, an amino group protected by a protecting group in nucleic acid synthesis, and a halogen atom.

Abstract: Disclosed are bridged nucleosides and nucleotides. The nucleosides of the present invention have a 2?,4?-bridged structure and are represented by formula I below: An oligonucleotide containing a 2?,4?-bridged artificial nucleotide of the present invention has a binding affinity for single-stranded RNA comparable to that of known 2?,4?-BNA/LNA and higher nuclease resistance than LNA. In particular, since the oligonucleotide has a much higher binding affinity for single-stranded RNA than S-oligo, it is expected that the oligonucleotide is applicable to nucleic acid drugs.

Abstract: Disclosed are bridged nucleosides and nucleotides. The nucleosides of the present invention have a 2?,4?-bridged structure and are represented by formula I below: An oligonucleotide containing a 2?,4?-bridged artificial nucleotide of the present invention has a binding affinity for single-stranded RNA comparable to that of known 2?,4?-BNA/LNA and higher nuclease resistance than LNA. In particular, since the oligonucleotide has a much higher binding affinity for single-stranded RNA than S-oligo, it is expected that the oligonucleotide is applicable to nucleic acid drugs.

Abstract: An oligonucleotide or a pharmacologically acceptable salt thereof of the present invention contains a compound represented by formula I or II or a salt thereof, and at least one of nucleoside structures represented by formula I? or II?. According to the present invention, provided is a nucleic acid molecule for oligonucleotides having high binding affinity and specificity to a target nucleic acid, and exhibiting high nuclease resistance.